标题：Rho/ROCK信号通路在阿尔茨海默病中的研究进展

      作者：裴海艳 1，万君 2，崔洁 2，王翔宇 1    三峡大学第三临床医学院葛洲坝集团中心医院神经内科 1、药学部 2，湖北 宜昌 443002

      卷次： 2019年30卷9期

      【摘要】 阿尔茨海默病(Alzheimer's disease，AD)是导致痴呆最常见的病因，随着人口的老龄化，患AD的人数逐年攀升，目前尚无有效的治疗方法。AD的发病机制尚未完全明了，目前认为其是一种多因素参与的疾病，其病理特征主要是β淀粉样蛋白(β-amyloid protein，Aβ)的沉积和神经纤维素的缠结(neurofibrillary tangles，NFT)。目前认为减少Aβ的产生能延缓或者预防AD的发展，而Rho/ROCK信号通路参与此病理过程，故Rho/ROCK抑制剂成为了AD治疗研究的新靶点。他汀类药物能抑制Rho/ROCK信号通路，为AD的治疗提供了新的思路，现将就AD、Rho/ROCK信号通路及他汀类药物之间的关系展开综述。
      【关键词】 阿尔茨海默病；Rho/ROCK信号通路；Aβ；抑制剂；他汀类药物
      【中图分类号】 R742.5 【文献标识码】 A 【文章编号】 1003—6350（2019）09—1187—03

Research progress of Rho/ROCK signaling pathway in Alzheimer's disease.
PEI Hai-yan 1, WAN Jun 2, CUI Jie 2,WANG Xiang-yu 1. Department of Neurology 1, Department of Pharmacy 2, Gezhouba Central Group Hospital, the ThirdCollege of Clinical Medical Science, China Three Gorges University, Yichang 443002, Hubei, CHINA【Abstract】 Alzheimer's disease (AD) is the most common cause of dementia. As the population ages, the num-ber of people with AD increases year by year. There is currently no effective treatment. The pathogenesis of AD has notbeen fully understood. It is currently considered to be a multifactorial disease. Its pathological features are mainly the de-position of beta-amyloid protein (Aβ) and the neurofibrillary tangles (NFT). At present, it is believed that reducing theproduction of Aβ can delay or prevent the development of AD. Rho/ROCK signaling pathway is involved in this patho-logical process, so Rho/ROCK inhibitors have become a new target for AD treatment research. Statins can inhibit Rho/ROCK signaling pathway, which provide new ideas for the treatment of AD. This review will summarize the relationshipbetween AD, Rho/ROCK signaling pathway and statins.
      【Key words】 Alzheimer’s disease; Rho/ROCK signaling pathway; Aβ; Inhibitor; Stains·综述·doi:10.3969/j.issn.1003-6350.2019.09.031基金项目：湖北省教育厅科研基金项目(编号：B2018012)；三峡大学青年科学基金项目(编号：KJ2016A018)